/jnci_2018

Recurrent gains in RET and HER2 signaling represent clinically actionable targets in breast cancer brain metastases

MIT LicenseMIT

jcni_2018

Recurrent gains in RET and HER2 signaling represent clinically actionable targets in breast cancer brain metastases